Quanterix Corporation filings document the regulatory record of a life sciences company built around ultra-sensitive biomarker instruments, consumables, assay services, and clinical laboratory testing. Its Form 8-K disclosures include operating and financial results, material-event reports, clinical or regulatory disclosures, capital-structure items, and leadership or board changes.
Proxy materials for QTRX describe annual meeting matters such as director elections, advisory executive compensation votes, auditor ratification, equity incentive plan approvals, and governance provisions. The filing record also covers shareholder voting results and charter-related governance matters, providing formal disclosure of the company’s board structure, compensation framework, ownership voting mechanics, and public-company controls.
Quanterix Corporation (QTRX) reported Q3 2025 results with total revenues of $40.2 million, up from $35.8 million a year ago, driven by stronger product revenue of $26.2 million versus $19.7 million. Service and other revenue was $14.0 million, roughly flat year over year. Gross profit was $17.2 million compared with $20.2 million, as costs rose with the expanding business.
The company recorded a net loss of $33.5 million (vs. $8.4 million), reflecting higher selling, general and administrative expenses of $39.1 million, $7.2 million of impairment and restructuring costs, and $5.2 million of Akoya acquisition-related costs. Year-to-date operating cash flow used was $60.8 million. Cash and cash equivalents were $38.3 million and marketable securities $96.5 million at September 30, 2025.
Quanterix closed the Akoya Biosciences acquisition on July 8, 2025, with total consideration of $151.0 million, including $49.2 million in stock, $18.9 million in cash to shareholders, $82.1 million to extinguish debt, and recognized $121.8 million of acquired intangible assets and $23.5 million of goodwill. The quarter included $1.2 million of non-cash revenue from amortizing an acquired off‑market contract liability.
Quanterix Corporation (QTRX) furnished an Item 2.02 update announcing financial results for the third quarter ended September 30, 2025. The company provided an earnings press release and accompanying presentation slides as exhibits. The information in this item, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act.
Exhibits include: 99.1 Earnings Release (November 10, 2025) and 99.2 Earnings Call Slides. The report was signed by Chief Financial Officer Vandana Sriram.
Quanterix (QTRX) reported an insider tax-withholding event by its President & CEO and Director. On October 31, 2025, 254 shares of common stock were withheld at $5.34 to cover taxes upon vesting of 761 RSUs.
After this transaction, the insider beneficially owns 511,442 shares, which includes 219,086 RSUs. The filing reflects routine administration of equity compensation rather than an open‑market sale.
Quanterix (QTRX) insider update: The Chief Financial Officer reported a tax-withholding transaction on 10/15/2025. Code F indicates 229 shares of common stock were withheld at $5.78 per share to satisfy taxes upon vesting of 777 restricted stock units.
Following this non‑open‑market event, the officer beneficially owns 86,742 shares, which includes 70,893 RSUs.
Quanterix Corp (QTRX) disclosed an insider transaction by its President & CEO and Director on 10/15/2025. The filing shows 1,242 shares of common stock were withheld (code F) at $5.78 per share to cover taxes upon the vesting of 3,722 RSUs.
Following this tax-withholding transaction, the reporting person beneficially owns 511,696 shares, which includes 219,847 RSUs. This is an administrative, non‑open market event tied to equity award vesting.
Quanterix Corp (QTRX) disclosed that a director acquired common stock through board compensation. On 10/01/2025, the director received 2,084 shares of common stock granted in lieu of cash fees for service on the Board and its committees for the third quarter of 2025. The grant was valued at the $5.54 closing price on the Nasdaq Global Market on that date.
Following this transaction, the director’s beneficial ownership was 29,488 shares, held directly, which includes 24,464 restricted stock units.
Quanterix Corporation director William P. Donnelly received 5,076 shares of common stock on 10/01/2025 as compensation in lieu of cash for board and committee service for the third quarter of 2025. The shares were recorded at the closing price of $5.54 on the Nasdaq Global Market for that date. Following the grant, Mr. Donnelly beneficially owns 148,374 shares, which include 12,955 restricted stock units. The Form 4 was filed individually and signed via attorney-in-fact on behalf of the reporting person.
Mendel Scott, a director of Quanterix Corp (QTRX), received 2,084 shares of common stock on 10/01/2025 as stock issued in lieu of cash board fees for Q3 2025 at a closing price of $5.54. Following the issuance, Mr. Scott beneficially owns 30,737 shares, which include 24,464 restricted stock units. The Form 4 was signed on behalf of the reporting person by Brian Keane, Attorney-in-Fact. The filing discloses no derivative transactions, option grants, or other cash purchases in this report.
Quanterix Corporation director Walt David R received 2,594 shares of common stock on 10/01/2025 as compensation in lieu of cash for third‑quarter 2025 board and committee fees, at the Nasdaq closing price of $5.54 per share. After the grant, the reporting person beneficially owns 1,871,675 shares, which include 7,435 restricted stock units. The Form 4 was signed by an attorney‑in‑fact on 10/03/2025. The filing discloses a single non‑derivative acquisition and explains the grant source and price; no options, dispositions, or additional derivative transactions are reported.
Quanterix Corporation reported results from its 2025 Annual Meeting of Stockholders held on September 29, 2025. Stockholders elected Myla Lai-Goldman, M.D., Masoud Toloue, Ph.D., and David R. Walt, Ph.D. to three-year terms on the board of directors, each receiving more than 29.7 million votes in favor.
Investors also approved, on an advisory basis, the compensation of the company’s named executive officers, with about 30.3 million votes for and 5.5 million against. KPMG LLP was ratified as independent registered public accounting firm with over 40.0 million votes for and minimal opposition.
Stockholders backed several governance changes. They approved an amendment to declassify the board of directors and separate amendments to remove supermajority stockholder vote requirements to change certain charter provisions and the company’s bylaws, each receiving approximately 35.6 million votes in favor.